Treatment of Latent Tuberculosis Infection in Adults
The preferred treatment for latent tuberculosis infection in adults is 3 months of once-weekly isoniazid plus rifapentine (3HP), which offers superior completion rates while maintaining excellent efficacy and tolerability compared to traditional longer regimens. 1
Preferred Regimens (in order of priority)
The 2020 CDC/National Tuberculosis Controllers Association guidelines establish a clear hierarchy of treatment options 1:
First-Line Preferred Options
3 months of isoniazid plus rifapentine given once weekly (3HP): This regimen has strong evidence with moderate quality data supporting its use 1. It achieves significantly higher treatment completion rates (87.5%) compared to other regimens (65.9%), while maintaining equivalent effectiveness in preventing active TB 2. The once-weekly dosing can be administered by directly observed therapy (DOT) or self-administered therapy (SAT) in adults 1.
4 months of daily rifampin: This has strong evidence with moderate quality data for HIV-negative adults 1. It demonstrates significantly better completion rates and less hepatotoxicity compared to isoniazid monotherapy 3.
3 months of daily isoniazid plus rifampin: This carries conditional recommendation with very low quality evidence in HIV-negative persons and low quality evidence in HIV-positive persons 1. While effective, hepatotoxicity risk may be greater with the two drugs combined than either alone 1.
Alternative Regimens
When preferred regimens cannot be used due to drug intolerability or drug-drug interactions 1:
6 months of daily isoniazid: Strong recommendation for HIV-negative adults, conditional for HIV-positive adults 1. This has efficacy exceeding 90% if completed properly, but suffers from poor adherence and carries hepatotoxicity risk 3.
9 months of daily isoniazid: Conditionally recommended for all adults 1. While historically the standard, this regimen has lower completion rates and higher hepatotoxicity compared to rifamycin-based regimens 4.
Special Populations and Drug Interactions
HIV-Positive Patients
3HP is now recommended for HIV-positive adults taking antiretroviral medications with acceptable drug-drug interactions with rifapentine 1. Concomitant use should be guided by clinicians experienced in managing both conditions 1.
Drug-drug interactions between rifamycins and antiretroviral therapy require careful review using updated guidelines from the U.S. Department of Health and Human Services 1.
In HIV-positive persons with low CD4+ counts, special consideration of drug interactions is critical 1.
When Rifampin is Contraindicated
- Weekly isoniazid and rifapentine (3HP) can be considered when rifampin is contraindicated due to drug-drug interactions, as rifapentine has fewer interactions than rifampin 1.
Comparative Efficacy and Safety
Network meta-analysis demonstrates that rifamycin-containing regimens for 3 months or more are efficacious at preventing active TB, potentially more so than isoniazid alone 5. Treatment with recommended regimens reduces the risk of progression to active tuberculosis (relative risk 0.35 at 5 years for 24 weeks of isoniazid vs placebo) 6.
Critical safety consideration: Isoniazid is associated with significantly higher rates of hepatotoxicity compared to rifampin (pooled relative risk 4.22) 6. The number needed to harm for hepatotoxicity with isoniazid is 279 6.
Monitoring for Adverse Events
For 3HP specifically 1:
Approximately 4% of patients experience flu-like or systemic drug reactions (fever, headache, dizziness, nausea, muscle pain, rash) typically occurring after the first 3-4 doses, beginning approximately 4 hours after medication ingestion 1.
Approximately 5% discontinue treatment due to adverse events 1.
Hypotension and syncope occur rarely (2 per 1,000 treated) 1.
Hepatic enzymes should be performed before initiation for certain high-risk patients 1.
Rifapentine induces metabolism of many medications, requiring monitoring when prescribed with interacting drugs (methadone, warfarin) and necessitating barrier contraception methods as it reduces hormonal contraceptive effectiveness 1.
Common Pitfalls to Avoid
Do not default to 9-month isoniazid simply due to familiarity—shorter rifamycin-based regimens have better completion rates and comparable or superior efficacy 2, 4.
Do not overlook drug-drug interactions particularly with antiretrovirals, hormonal contraceptives, and other medications metabolized by cytochrome P450 1.
Do not fail to exclude active TB before initiating treatment—this is critical to prevent acquired drug resistance 1.
Do not assume all patients require directly observed therapy—self-administered therapy is appropriate for many adults receiving 3HP, with the choice based on individual patient attributes and risk for progression to severe TB 1.